Drug Profile
Research programme: antibacterials - AriBio
Alternative Names: AR 1004Latest Information Update: 28 Jul 2020
Price :
$50
*
At a glance
- Originator AriBio
- Class Antibacterials; Quinolones
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Pneumonia
Most Recent Events
- 28 Jul 2020 No recent reports of development identified for preclinical development in Pneumonia in South Korea
- 01 Jun 2016 Preclinical trials in Pneumonia in South Korea (unspecified route)